Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Issue 11 (November 2015)

• Record Type: Journal Article
• Authors: Miyashita, Kazuho; Tomita, Naoto; Taguri, Masataka; Suzuki, Taisei; Ishiyama, Yasufumi; Ishii, Yoshimi; Nakajima, Yuki; Numata, Ayumi; Hattori, Yukako; Yamamoto, Wataru; Miyazaki, Takuya; Tachibana, Takayoshi; Takasaki, Hirotaka; Matsumoto, Kenji; Hashimoto, Chizuko; Takemura, Sachiya; Yamazaki, Etsuko; Fujimaki, Katsumichi; Sakai, Rika; Motomura, Shigeki; Ishigatsubo, Yoshiaki
• Is Part Of: Leukemia research. Volume 39:Issue 11(2015:Nov.)
• Page Start: 1187
• Page End: 1191
• Publication Date: 2015-11
• Subjects: Diffuse large B-cell lymphoma -- Non-hodgkin lymphoma -- Beta 2-microglobulin -- R-CHOP -- Progression-free survival; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2015.08.016
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: DLBCL patients are routinely examined many biomarkers. We analyzed 319 DLBCL patients received R-CHOP therapy. Progression-free survival was the endpoint of this retrospective study. We decided the most useful biomarker to predict the prognosis of DLBCL patients. Beta-2 microglobulin is a useful prognostic indicator for DLBCL patients in R era. Abstract: Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy between 2003 and 2012. We assessed the prognostic significance of six biomarkers [lactate dehydrogenase, soluble interleukin-2 receptor, thymidine kinase activity, beta-2 microglobulin (B2M), C-reactive protein, and ferritin] and representative clinical characteristics using progression-free survival (PFS) as the endpoint. The study group included 181 men and 138 women with a median age of 63 years (range, 22–89 years). In a multivariate analysis, the serum B2M level most strongly correlated with PFS (hazard ratio, 2.11; P = 0.04). In a univariate analysis, patients with serum B2M levels >1.75 μg/mL ( n = 210) had a worse 3-year PFS rate (71.2%) than those with B2M levels< 1.75 μg/mL ( n = 109; 90.0%). Therefore, serum B2M level at the time of diagnosis is a useful prognostic indicator in DLBCL patients receiving R-CHOP.